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Despite the availability of multiple safe vaccines, vaccine hesitancy may present a challenge
to successful control of the COVID-19 pandemic. As with many human behaviors, people’s
vaccine acceptance may be affected by their beliefs about whether others will accept a vaccine
(i.e., descriptive norms). However, information about these descriptive norms may have dif-
ferent effects depending on people’s baseline beliefs and the relative importance of conformity,
social learning, and free-riding. Here, using a large, pre-registered, randomized experiment
(N=484,239) embedded in an international survey, we show that accurate information about
descriptive norms can substantially increase intentions to accept a vaccine for COVID-19. These
positive effects (e.g., reducing by 4.9% the fraction of people who are “unsure” or more negative
about accepting a vaccine) are largely consistent across the 23 included countries, but are con-
centrated among people who were otherwise uncertain about accepting a vaccine. Providing
this normative information in vaccine communications partially corrects individuals’ apparent
underestimation of how many other people will accept a vaccine. These results suggest that
public health communications should present information about the widespread and growing
intentions to accept COVID-19 vaccines.
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Nonpharmaceutical interventions in response to epidemics, such as the COVID-19 pandemic,
often depend on the behavioral responses of the public for their effectiveness. Even with the
availability of vaccines, success depends on people’s choices to accept, or even seek out, the
vaccine1, since even low vaccine refusal rates can prevent achieving herd immunity2,3. Given the
value of individual autonomy and the significant challenges of imposing vaccine mandates4–6,
it is important to understand how public health messaging can increase acceptance of safe
and effective COVID-19 vaccines. Many messaging strategies address individual barriers to
vaccination, such as complacency and inconvenience7, as well as perceived risk of both vaccines
and the disease1. However, these strategies may have important limitations; for example,
field studies show that corrective information about vaccine safety can effectively reduce
misconceptions and false beliefs, though they are not as effective in changing vaccine-related
intentions8,9. Messaging strategies that share recommendations from experts and emphasize
reasons for accepting a vaccine have shown promising effects on increasing acceptance in the
United States10.
It may be important to look beyond individuals to consider how public health messaging
can also leverage the significant roles of social networks (broadly defined) in shaping individual
vaccination decisions11–15. Rather than being a small factor, there is growing evidence that
people’s preventative health behaviors are dramatically influenced by many social and cultural
factors, with implications for COVID-1916. In the United States, for example, analyses of
mobility data during the COVID-19 pandemic revealed that people’s mobility behaviors vary
with their partisan affiliation17 and media consumption18,19 and are affected by the behaviors
of their social connections20.
Acceptance of COVID-19 vaccines likely involves substantial social influence, but theory
is not entirely clear on whether learning that others’ are accepting a vaccine will increase
or decrease acceptance. Positive peer effects can arise due to information diffusion21,22,
conformity and injunctive norms14, inferring vaccine safety and effectiveness from others’
choices23,24, or pro-social motivations such as altruism25,26 and reciprocity27. On the other
hand, negative effects of others’ acceptance can arise as a result of free-riding on vaccine-
generated herd immunity, even if only partial or local28,29. The empirical evidence on when
positive peer effects24,30,31 or free-riding28 may dominate is inconclusive. Furthermore, the
effects of incorporating truthful information about others’ into messaging strategies will depend
on what that information is, i.e., how prevalent is vaccine acceptance in a given reference
group? Thus, we need further empirical guidance about scalable and effective messaging
strategies leveraging social influence. That is, while some interpretations of the theoretical
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Survey wave (July 2020 through March 2021), by country
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Fig. 1. There is substantial country-to-country variation in levels and trends in COVID-19 vaccine acceptance
from July 2020 to March 2021. Shown are the 23 countries with repeated data collection over time. “Yes”
also includes respondents indicating they already received a vaccine. (inset) Pooling data from all 23
countries, people who believe a larger fraction of their community will accept a vaccine are on average more
likely to say they will accept a vaccine; this is also true within each included country (Figure S16).
and empirical literature could motivate emphasizing high rates of vaccine acceptance in public
health communications, little is known about how realistic interventions of using messages
with factual information about others’ vaccine acceptance will affect intentions to accept the
new COVID-19 vaccines.
Here we provide evidence, from a large-scale randomized experiment embedded in an
international survey, that information about descriptive norms — what other people do,
believe, or say — can have substantial positive effects on intentions to accept new vaccines
for COVID-19. To our knowledge, there are no other quantitative causal assessments of how
exposure to factual descriptive norms affects intentions to receive the COVID-19 vaccines.
Through a collaboration with Facebook and Johns Hopkins University, and with input
from experts at the World Health Organization and the Global Outbreak Alert and Response
Network, we fielded a survey in 67 countries in their local languages, yielding over 2.0 million
responses to date32. This survey assessed people’s knowledge about COVID-19, beliefs about
and use of preventative behaviors, beliefs about others’ behaviors and beliefs, and economic
experiences and expectations. Recruitment to this survey was via prominent messages from













Facebook to its to users that encouraged potential respondents to help with research on
COVID-19 (Figure S4). While it is often impossible to account for all factors that may
jointly determine selection into the sample and survey responses, our collaboration with
Facebook allows using state-of-the-art, privacy-preserving weighting for non-response using
rich behavioral and demographic variables, as well as further weighting to target the adult
population of each country32,33. All analyses presented here use these survey weights to ensure
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Fig. 2. Within-country distributions of beliefs about descriptive norms (“Out of 100 people in your community,
how many do you think would take a COVID-19 vaccine if it were made available?”) during the experimental
period (October 2020 to March 2021). To enable comparison with actual country-wide potential vaccine
acceptance, these histograms are colored by whether they are below (red) the narrow (“Yes” only) definition
of vaccine acceptance, between (yellow) the narrow and broad (“Yes” and “Don’t know”) definitions, or above
(teal) the broad definition.
This survey has documented substantial variation in stated intentions to take a vaccine
for COVID-19 when one is available to the respondent, with, for example, some countries
having much larger fractions of people saying they will take a vaccine than others (Figure
1); however, a plurality consistently say they will accept a vaccine and only a (often small)
minority say they will refuse one. This is consistent with other smaller-scale national10,34 and













international35 surveys. There is also substantial variation in what fraction of other people
respondents think will accept the vaccine, and these beliefs often substantially differ from
country-wide levels of vaccine acceptance (Figure 2). This deviation can have multiple causes,
including responding with round numbers; but we posit this is at least partially because some
people have incorrect beliefs about descriptive norms. Underestimation of vaccine acceptance
by others could be partially caused by processes — such as news coverage of the challenges
posed by vaccine hesitancy or diffusion of anti-vaccine messages on social media — that make
hesitancy more salient. Beliefs about descriptive norms are in turn positively correlated with
vaccine acceptance (Figure 1 inset, Figure S16), likely reflecting many processes, like geographic
and social clustering of vaccine hesitancy, but also causal effects of beliefs about others on
intentions to accept a vaccine. Public health communications could present information about
norms, perhaps correcting some people’s overestimation of the prevalence of vaccine hesitancy.
Unlike other ongoing, frequently observable preventative behaviors, like mask wearing, people
may have little information about whether others intend to or have accepted a vaccine —
which suggests messages with this information could have particularly large effects.
Randomized Experiment
To learn about the effects of providing normative information about new vaccines, beginning
in October 2020, for the 23 countries with ongoing data collection in this study, we provided
respondents with accurate information about how previous respondents in their country had
answered a survey question about vaccine acceptance, mask wearing, or physical distancing.
We randomized at what point in the survey this information was provided, which behavior the
information was about, and how we summarized previous respondents’ answers — enabling us
to estimate the effects of providing information about descriptive norms on people’s stated
intentions to accept a vaccine.
In the case of vaccine acceptance, we told some respondents, “Your responses to this survey
are helping researchers in your region and around the world understand how people are
responding to COVID-19. For example, we estimate from survey responses in the previous
month that X% of people in your country say they will take a vaccine if one is made available”,
where X is the (weighted) percent of respondents saying “Yes” to a vaccine acceptance question.
Other respondents received information on how many “say they may take a vaccine”, which is
the (weighted) percent who chose “Yes” or “Don’t know” for that same question. Whether this
information occurs before or after a more detailed vaccine acceptance question∗ and whether
∗When the detailed vaccine acceptance question occurs after the normative information, it is always separated by at least
one intervening screen with two questions, and it is often separated by several screens of questions (Figure S15a). Most
questions were unrelated to social norms or vaccines32.
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Fig. 3. (a) The normative information treatments shift people to higher levels of vaccine acceptance, whether
compared with receiving no information (control) or information about other, non-vaccine-acceptance norms
(other behavior ). (b) These estimated effects are largest for respondents who are uncertain about accepting
a vaccine at baseline and respondents with baseline beliefs about descriptive norms that are under (rather
than above or between) both of the levels of normative information provided in the treatments. (c) While there
is some country-level heterogeneity in these effects, point estimates of the effect of the broad normative
information treatment are positive in all countries. Error bars are 95% confidence intervals.
it uses the broad (combining “Yes” and “Don’t know”) or narrow (“Yes” only) definition of
potential vaccine accepters is randomized — allowing us to estimate the causal effects of
this normative information. Here we focus on comparisons between providing the normative
information about vaccines before or after measuring outcomes (e.g., vaccine acceptance); in
the Supplementary Information (SI), we also report similar results when the control group
consists of those who received information about other behaviors (i.e., about mask wearing
and distancing), which can avoid concerns about differential attrition and researcher demand.
On average, presenting people with this normative information increases stated intentions
to take a vaccine, with the broad and narrow treatments causing 0.039 and 0.033 increases on
a five-point scale (95% confidence intervals: [0.028, 0.051] and [0.021, 0.044], respectively).
The distribution of responses across treatments (Figure 3a) reveals that the effects of the













broad (narrow) treatment are concentrated in inducing an additional 1.6% (1.1%) of people to
say they will at least “probably” accept the vaccine,† and moving 1.9% (1.7%) to “definitely”
(Table S8). This is a 4.9% relative reduction in the fraction of people choosing a response that
is “unsure” or more negative. A post hoc analysis also concluded that these effects are largest
among people who answer “Don’t know” to the baseline vaccine acceptance question (Figure
3b, Table S12), consistent with the idea of targeting vaccine “fence-sitters”36. These effects
are relatively large and are of similar overall magnitude as global trends in vaccine acceptance
from November 2020 to January 2021 (0.11 increase on the five-point scale) — a period that
featured frequent and widely-distributed vaccine-related news.‡
These effects on vaccine acceptance can be at least partially explained by changes in
respondents’ beliefs about these descriptive norms. We can examine this because the survey
also measured respondents’ beliefs about vaccine acceptance in their communities (as displayed
in Figure 2), and we randomized whether this was measured before or after providing the
normative information. As expected, the normative information treatment increased the
fraction of people that the respondents estimate will accept a vaccine (Figure S8). Among
those respondents for whom we measured these normative beliefs prior to treatment, we
can examine how treatment effects varied by this baseline belief. In particular, we classify
respondents according to whether their baseline belief was above the broad (“may take”)
number, under the narrow (“will take”) number, or between these two numbers.§ Consistent
with the hypothesis that this treatment works through revising beliefs about descriptive norms
upwards, we find significant effects of the normative information treatment in the groups that
may be underestimating vaccine acceptance — the under and between groups (Figure 3b),
though the smaller sample sizes here (since these analyses are only possible for a random
subset of respondents) do not provide direct evidence that the effect in the under group is
larger than that in the above group (p = 0.38 and p = 0.31 for broad and narrow treatments,
respectively).¶ A post hoc analysis to address possible mismeasurement due to a preference
to report round numbers (by removing those who reported they believe 0%, 50%, or 100% of
people in their community would accept a vaccine) provided was likewise consistent with this
†Note that this statement is about effects on the cumulative distribution of the vaccine acceptance scale (the proportion
answering at least “Probably”). The proportion answering exactly “Probably” is similar across conditions (Figure 3a),
consistent with the treatment shifting some respondents from “Unsure” to “Probably” but also some from “Probably”
to “Definitely”.
‡This detailed vaccine acceptance question was only shown to people who had reported not having already received a
vaccine. Therefore, for this comparison, we restrict to the time period before vaccines were available to the public in
countries in our sample.
§The question measuring beliefs about descriptive norms asks about “your community”, while the information provided
is for the country. Thus, for an individual respondent, these need not exactly match to be consistent.
¶We had also hypothesized that the broad and narrow treatments would differ from each other in their effects on
respondents in the between group, but we found no such evidence, p = 0.87.














Having fielded this experiment in 23 countries, we can estimate and compare treatment effects
internationally, which may be useful for both national and international communication efforts.
Using a linear mixed-effects model, we estimate positive effects in the majority of countries
(Figure 3c). While estimates for some countries are larger (e.g., Pakistan, Vietnam) and some
are smaller (e.g., Nigeria, United Kingdom), most countries are statistically indistinguishable.
Furthermore, point estimates of the effect of the broad treatment are nearly uniformly positive.
Thus, we summarise the results as providing evidence that accurate normative information
consistently increases intentions to accept COVID-19 vaccines.
Limitations and Robustness of the Conclusions
The primary drawback of the approach taken in this paper is that we are only able to measure
changes in intentions to accept a vaccine against COVID-19, which could differ from vaccine
uptake. While it is not possible at this stage to study interventions that measure take up of
the COVID-19 vaccine on a representative global population, we believe that the intervention
studied here is less subject to various threats to validity — such as experimenter demand
effects — that are typically a concern in survey experiments measuring intentions.
This randomized experiment was embedded in a survey with a more general advertised
purpose that covers several topics, so normative information is not particularly prominent
(Figure S4). In this broader survey, only 15% of questions were specific to vaccinations or
social norms32. Furthermore, unlike other sampling frames with many sophisticated study
participants (e.g., country-specific survey panels, Amazon Mechanical Turk), respondents are
recruited from a broader population (Facebook users). In addition, we observe null results
for observable behaviors such as distancing and mask wearing, which would be surprising if
researcher demand effects were driving the result.
A number of robustness checks increase our confidence that experimenter demand is not
driving the result. As a first robustness check, we compare the outcome of subjects who
receive the vaccine norm treatment to those receiving the treatment providing information
about masks and distancing and find the treatment effect persists (Table S9). Moreover, we
may expect researcher demand effects to be smaller when the information treatment and the
outcome are not immediately adjacent. In all cases, for the vaccine acceptance outcome, there
is always at least one intervening screen of questions (the future mask-wearing and distancing
intentions questions). Furthermore, they are often separated by more than this. We consider
a subset of respondents where the treatment and the outcome are separated by at least one
“block” of questions between them. Results of this analysis are presented in Figure S14 and
Table S13. The estimated effects of the vaccine treatments in this smaller sample are less












precise, but both significantly positive.‖ Moreover, Table S14 shows even with the larger gap
between treatment and outcome the information is still moving a relatively large share of
people who are unsure or more negative to at least probably accepting the vaccine.
Discussion
Framing vaccination as a social norm has been suggested as an effective approach to building
COVID-19 vaccine confidence15,37–39, but this recommendation has lacked direct evidence on a
scalable messaging strategy, which this international randomized experiment now contributes.
Brewer et al.15 document the case of a vaccine campaign by a major pharmacy retail chain in
the United States that employed negative norms messaging to emphasize risks to individuals:
“Get your flu shot today because 63% of your friends didn’t.” Although such a strategy can
reduce incentives to free-ride on vaccine herd immunity, its broader impact on social norm
perceptions may render it ineffective. In general, the multimodal effects of descriptive norms on
risk perceptions, pro-social motivations, and social conformity highlight the value of evidence
from a large-scale study as we provide here.
For social norms to be effective it is critical that they are salient in the target population
(e.g., wearing badges40). While in our randomized experiments norms are made salient through
direct information treatments, the results have implications for communication to the public
through health messaging campaigns and the news media. For example, because very high
levels of vaccine uptake are needed to reach herd immunity3, it is reasonable for news media to
cover the challenges presented by vaccine hesitancy; but our results suggest that it is valuable
to contextualize such reporting by highlighting the widespread norm of accepting COVID-19
vaccines. Public health campaigns to increase acceptance of safe and effective vaccines can
include information about descriptive norms. In an effort to influence the public, some public
figures have already documented receiving a COVID-19 vaccine in videos on television and
social media. The substantial positive effects of numeric summaries of everyday people’s
intentions documented here suggest that simple factual information about descriptive norms
can similarly leverage social influence to increased vaccine acceptance. Some negative attitudes
toward vaccination put disadvantaged communities at more risk, so emphasizing country-wide
vaccination norms may prove critical for removing susceptible pools and reducing the risk of
endemic disease3,41.
How important are the effects of the factual descriptive normative messages studied here?
Smaller-scale interventions that treated individuals with misinformation42, pro-social mes-
sages43, demographically tailored videos44, text message reminders45, or other informational
‖For vaccines, the treatment effects muted somewhat as the p-values that the treatment effect is equal across this smaller
sample and the broader sample are 0.02 and 0.03 for the broad and narrow treatments, respectively.













content46 have yielded similar or smaller effect sizes, while lacking the scalability and practical
appeal of accurate descriptive norms. The substantial effects of normative information about
vaccine acceptance may reflect that people have little passive exposure to information about
how many people in their communities and countries would accept a vaccine, or even have
done so already. This result contrasts with other preventative behaviors (mask wearing and
distancing), for which we observe smaller or no effects (see Supplementary Information Section
S6), that are both ongoing (i.e., respondents have repeatedly chosen whether to perform
them before) and readily observable in public. However, it is possible that as people have
more familiarity with social contacts choosing to accept a vaccine, this type of normative
information will become less impactful, making the use of this communication strategy even
more important in the early stages of a vaccine roll out to the most vulnerable people in
each country. More generally, changes in stated intentions to accept a vaccine may not fully
translate into actual take-up, though prior studies exhibit important concordance between
vaccination intentions and subsequent take-up47 — and effects of treatments on each48,49.
Thus, we encourage the use of these factual normative messages, as examined here; but we
also emphasize the need for a range of interventions that lower real and perceived barriers to
vaccination, as well as leveraging descriptive norms and social contagion more generally, such
as in spreading information about how to obtain a vaccine21.
Materials and Methods
Experiment analysis.The results presented in the main text and elaborated on in the supple-
mentary materials each use a similar pre-registered methodology that we briefly describe here.
For the results in Figure 3a, we estimate the following linear regression for each behavior k:










ik + εik, [1]
where Yik is the outcome for individual i and behavior k ∈ K = {vaccine, distancing, masks},
Djik is an indicator if individual i received treatment j ∈ J = {Broad, Narrow} for behavior k,
and Xi is a vector of centered covariates50,51. All statistical inference uses heteroskedasticity-
consistent Huber–White “sandwich” estimates of the variance–covariance matrix.
For heterogeneous treatment effects (Figure 3b), we estimate a similar regression focusing































Mixed-effects model. In the main text and Figure 3c, we report results from a linear mixed-
effects model with coefficients that vary by country. This model is also described in our
preregistered analysis plan. Note that the coefficients for the overall (across-country) treatments
effects in this model differ slightly from the estimates from the model in equation 3; that is,
the “Average” points in Figure 3b and 3c do not match exactly. As noted in our analysis plan,
“sandwich” standard errors are not readily available here, so reported 95% confidence intervals
are obtained by estimating the standard errors via a bootstrap.
Data and materials and availability.Documentation of the survey instrument and aggregated
data from the survey are publicly available at https://covidsurvey.mit.edu. Researchers can
request access to the microdata from Facebook and MIT at https://dataforgood.fb.com/doc
s/preventive-health-survey-request-for-data-access/. Researchers can request access to the
microdata at [redacted]. Preregistration details are available at https://osf.io/9sk4h/?view_o
nly=aa44d784c2c34d02beeaa9e45be8317f and https://osf.io/vg786/?view_only=62557532
b8564a0caae601dfedde1b55. Analysis code for reproducing the results will be made public.
The Committee on the Use of Humans as Experimental Subjects at MIT approved both the
survey and embedded randomized experiment as exempt protocols.
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During an update to the survey on October 28th, 2020, we introduced a prompt to all
respondents that provided information about preventative behaviors in their country based
on information from the survey. Although this information was provided to all respondents
who completed the survey from an eligible country, the information was provided in a random
order creating an experiment within the survey. For each eligible respondent, we showed the
following message at a random position in the latter part of the survey:
Your responses to this survey are helping researchers in your region and around
the world understand how people are responding to COVID-19. For example, we
estimate from survey responses in the previous month that [[country share]]% of
people in your country say they [[broad or narrow]] [[preventative behavior]].
We filled in the blanks with one randomly chosen preventative behavior, a broad or narrow
definition of the activity, and the true share of responses for the respondent’s country. The
three behaviors were vaccine acceptance, mask wearing, and social distancing. In the broad
condition, we used a more inclusive definition of the preventative behavior and the narrow
condition used a more restrictive definition. For example, for vaccine acceptance we either
reported the share of people responding “Yes” or the share of people responding “Yes” or
“Don’t know” to the baseline vaccine acceptance question. The numbers shown, which are
updated with each wave, are displayed in Figure S6.
We preregistered our analysis plan, which we also updated to reflect continued data
collection and our choice to eliminate the distancing information treatment in later waves.
While we describe some of the main choices here, our pregistered analysis plans can be
viewed at https://osf.io/9sk4h/?view_only=aa44d784c2c34d02beeaa9e45be8317f and
https://osf.io/vg786/?view_only=62557532b8564a0caae601dfedde1b55. The analysis of the
experiment in the main text that is not described in the analysis plan is labeled post hoc (in
particular, heterogeneity by baseline vaccine acceptance). One set of more complex analyses
speculatively described in the analysis plan (hypothesis 3, “may suggest using instrumental
variables analyses”) has not yet been pursued.
S2. Data construction
Our dataset is constructed from the microdata described in (author?) S32 . We first code each
outcome to a 5-point numerical scale. We then condition on being eligible for treatment and
having a waves survey type (i.e. being in a country with continual data collection) to arrive










(a) Facebook Recruitment Message (b) Facebook Interstitial
Fig. S4. Facebook Promotion and Interstitial
at the full dataset of those eligible for treatment.∗∗ All randomization and balance checks
∗∗Respondents in the snapshot survey may have received treatment if they self-reported being in a wave country. Their
weights, however, will be wrong as their country will disagree with the inferred country so they are excluded.













described as “intent-to-treat” use this dataset. In our preregistered analysis plan, we described
how the sample would be restricted to those who completed the survey and for whom we
received a full survey completion weight from Facebook. This removes approximately 40% of
respondents, resulting in 484,239 respondents. For the main analysis comparing users who
received the vaccine information treatment to control users (e.g., in Figure 3b), there are
365,593 respondents.
As in our pre-analysis plan, the following variables are used in our analysis:
1. Outcomes
(a) Over the next two weeks, how likely are you to wear a mask when in public?
[Always, Almost always, When convenient, Rarely, Never]
(b) Over the next two weeks, how likely are you to maintain a distance of at least 1
meter from others when in public? [Always, Almost always, When convenient,
Rarely, Never]
(c) If a vaccine against COVID-19 infection is available in the market, would you take
it? [Yes, definitely, Probably, Unsure, Probably not, No, definitely not]
2. Mediators & Covariates
(a) Baseline outcomes. These questions are similar to the outcome questions. Only
the vaccine question always appears before the treatment in all cases; the others
are in a randomized order. Thus, for use of the other covariates for increasing
precision, mean imputation is required.
• Masks. How often are you able to wear a mask or face covering when you are
in public? How effective is wearing a face mask for preventing the spread of
COVID-19?
• Distancing: How often are you able to stay at least 1 meter away from people
not in your household? How important do you think physical distancing is
for slowing the spread of COVID-19?
• Vaccine: If a vaccine for COVID-19 becomes available, would you choose
to get vaccinated? This will be coded as binary indicators for the possible
outcomes, grouping missing outcomes with “Don’t know”.
(b) Beliefs about norms. These questions will be randomized to be shown before
the treatment for some respondents and after treatment for other respondents.













This will allow us to study heterogeneity in baseline beliefs, as well as ensure our
randomization does impact beliefs.
• Masks: Out of 100 people in your community, how many do you think do the
following when they go out in public? Wear a mask or face covering.
• Distancing: Out of 100 people in your community, how many do you think
do the following when they go out in public? Maintain a distance of at least
1 meter from others.
• Vaccine: Out of 100 people in your community, how many do you think would
take a COVID-19 vaccine if it were made available?
When used in analysis, we require all covariates to be before both treatment and outcome.
As the survey contains randomized order for these questions, this ensures that the distribution
of question order is the same across treated and control groups and removes any imbalance
created by differential attrition. Missing values are imputed at their (weighted) mean.
S3. Randomization checks
Table S1 presents results of a test that the treatment and control shares were equal to 50% as
expected. While the final dataset does have some evidence of imbalance that could be caused
by differential attrition, the “robust” dataset (described in S6.2) is well balanced and the
treatment is balanced across the three behaviors information could be provided about (Table
S2). According to our pre-registered analysis plan, in the presence of evidence of differential
attrition, we make use of additional analyses that use the information about other behaviors
as an alternative control group throughout this supplement.
Table S1. Randomization Tests
p-val Treated Share Control Share
Full 0.011 0.501 0.499
Final 0.081 0.499 0.501
Robust 0.176 0.499 0.501
The results of a test that the treated share and control shares equal 50%. The first row uses
intent-to-treat on the full set of eligible respondents, the second row uses the final data set after
conditioning on eligibility and completing the survey, and the third row uses the subset of responses
in the final dataset that have at least one block between treatment and outcome.
In addition, baseline covariates measured before both treatment and the outcome are
balanced across treatment and control groups (Table S3). The covariates are also balanced
in the final analysis dataset (Table S4) and within treated users across the three possible
treatment behaviors (Table S5).












Table S2. Randomization Tests
Vaccine Masks Distancing
Final 0.215 0.218 0.441
Robust 0.210 0.113 0.519
The p-values of a test that each behavior was shown the expected number of times. This reports
the results of a joint test that each period share was equal to the expected. For waves 9-12, each
behavior was shown 1/3 of the time and for waves 12 on the vaccine treatments were shown to
2/3 of respondents and the mask treatments were shown to 1/3 of respondents. This table cannot
include the full dataset intent-to-treat analysis because the behavior randomization occurred when
the treatment was shown.


















































































Fig. S5. Treatment Variation
For each behavior (Vaccine, Masks, Distancing), we plot the information provided to subjects based
on the broad and narrow definitions of compliance. The treatments were updated every two weeks
as new waves of data were included. The points labeled “country belief” display the weighted
average belief in a country of how many people out of 100 practice (or will accept, for vaccines)
each behavior.















• Baseline vaccine acceptance
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Fig. S6. Experiment Flow
Illustration of the flow of a respondent through the survey. First, they are presented with tracking
and demographic questions. They then enter a randomized portion where blocks are in random
order. This includes the treatment, outcome, and many of the baseline covariates included in
regressions for precision. Recall all covariates used in analysis are only used if they are pre-treatment
and outcome.
























(a) Balance Tests: Intent-to-treat











(b) Balance Tests: Final Sample












(c) Balance Tests: Vaccine vs Mask Treatments












(d) Balance Tests: Vaccine vs Dist Treatments
Fig. S7. Balance Test p-Values
Ordered p-values for the balance tests described in Tables S3, S4, and S5 sorted in ascending
order. All available pre-treatment covariates are included, which results in 76 tests. This includes
roughly 40 covariates that are not presented in the tables for brevity. These are questions that
permit multiple responses, including news media, sources, and trust, and a more detailed list of
preventative measures taken.













Table S3. Balance Tests: Intent-to-treat
p-val Control Treated
age 0.223 2.587 (0.002) 2.583 (0.002)
gender 0.401 1.441 (0.001) 1.440 (0.001)
education 0.468 2.781 (0.001) 2.779 (0.001)
own health 0.068 2.410 (0.002) 2.414 (0.002)
vaccine accept 0.848 1.491 (0.001) 1.491 (0.001)
knowledge existing treatments 0.210 0.218 (0.001) 0.219 (0.001)
info exposure past week 0.439 2.300 (0.001) 2.301 (0.001)
info exposure more less wanted 0.614 2.387 (0.002) 2.386 (0.002)
know positive case 0.405 1.281 (0.002) 1.279 (0.002)
prevention mask 0.999 3.607 (0.002) 3.607 (0.002)
prevention distancing 0.769 2.669 (0.003) 2.670 (0.003)
prevention hand washing 0.526 3.299 (0.002) 3.297 (0.002)
effect mask 0.641 2.983 (0.003) 2.981 (0.003)
effect hand washing 0.195 2.996 (0.003) 2.991 (0.003)
country management 0.082 1.831 (0.004) 1.822 (0.004)
community management 0.878 1.929 (0.003) 1.928 (0.003)
community action importance 0.498 3.354 (0.002) 3.352 (0.003)
community action norms 0.458 2.737 (0.003) 2.734 (0.003)
distancing importance 0.803 3.112 (0.003) 3.111 (0.003)
norms dist 0.221 49.008 (0.091) 49.162 (0.090)
norms masks 0.648 71.800 (0.086) 71.852 (0.086)
norms vaccine 0.837 61.939 (0.087) 61.917 (0.086)
risk community 0.164 2.541 (0.005) 2.531 (0.005)
risk infection 0.638 2.165 (0.005) 2.168 (0.005)
control infection 0.515 1.879 (0.006) 1.873 (0.006)
infection severity 0.083 1.272 (0.003) 1.264 (0.003)
employed 2020 0.542 0.725 (0.002) 0.727 (0.002)
Pre-treatment covariate means for all respondents who were eligible for treatment in both the
treatment and control groups along with the p-value for the test of the null that the means are
equal. For each covariate, only responses where the covariate is not missing and occurs before both
treatment and control are included. To account for changes to the sampling frequencies, these
p-values are from the coefficient on the intent-to-treat term in a regression of the covariate on
treatment, period, and centered interactions between treatment and period. As we do not have
weights for all respondents, this is an unweighted regression.













Table S4. Balance Tests: Final Dataset
p-val Control Treated
age 0.855 2.697 (0.003) 2.696 (0.003)
gender 0.757 1.442 (0.001) 1.441 (0.001)
education 0.446 2.826 (0.002) 2.826 (0.002)
own health 0.828 2.394 (0.002) 2.398 (0.002)
vaccine accept 0.710 1.510 (0.002) 1.510 (0.002)
knowledge existing treatments 0.417 0.213 (0.001) 0.211 (0.001)
info exposure past week 0.417 2.367 (0.002) 2.371 (0.002)
info exposure more less wanted 0.875 2.410 (0.002) 2.409 (0.002)
know positive case 0.029 1.329 (0.002) 1.325 (0.002)
prevention mask 0.181 3.640 (0.003) 3.643 (0.003)
prevention distancing 0.132 2.709 (0.004) 2.716 (0.004)
prevention hand washing 0.445 3.333 (0.003) 3.335 (0.003)
effect mask 0.155 2.996 (0.003) 2.990 (0.003)
effect hand washing 0.315 3.014 (0.003) 3.011 (0.003)
country management 0.537 1.796 (0.004) 1.782 (0.004)
community management 0.964 1.904 (0.004) 1.900 (0.004)
community action importance 0.747 3.371 (0.003) 3.369 (0.003)
community action norms 0.717 2.712 (0.004) 2.705 (0.004)
distancing importance 0.279 3.150 (0.003) 3.149 (0.003)
norms dist 0.028 49.517 (0.107) 49.797 (0.107)
norms masks 0.041 72.605 (0.101) 72.918 (0.101)
norms vaccine 0.871 62.591 (0.101) 62.572 (0.101)
risk community 0.163 2.564 (0.006) 2.544 (0.006)
risk infection 0.756 2.205 (0.006) 2.211 (0.006)
control infection 0.557 1.885 (0.007) 1.874 (0.007)
infection severity 0.011 1.269 (0.004) 1.257 (0.004)
employed 2020 0.415 0.725 (0.002) 0.728 (0.002)
Pre-treatment covariate means for all respondents who were eligible for treatment, completed the
entire survey, and received a full survey completion weight in both the treatment and control
groups along with the p-value for the test of the null that the means are equal. For each covariate,
only responses where the covariate is not missing and occurs before both treatment and control
are included. To account for changes to the sampling frequencies, these p-values are from the
coefficient on the treatment term in a regression of the covariate on treatment, period, and centered
interactions between treatment and period. This is a weighted regression using full completion
survey weights.













Table S5. Balance Tests Between Treatments: Final Dataset
VD p-val VM p-val Vaccine Masks Dist
age 0.543 0.011 2.716 2.684 2.611
gender 0.229 0.630 1.440 1.442 1.445
education 0.861 0.313 2.825 2.826 2.839
own health 0.278 0.629 2.399 2.401 2.386
vaccine accept 0.419 0.000 1.524 1.505 1.442
knowledge existing treatments 0.308 0.926 0.159 0.209 0.555
info exposure past week 0.294 0.633 2.375 2.369 2.354
info exposure more less wanted 0.339 0.361 2.420 2.404 2.355
know positive case 0.825 0.894 1.339 1.326 1.233
prevention mask 0.920 0.391 3.649 3.640 3.609
prevention distancing 0.479 0.551 2.723 2.711 2.687
prevention hand washing 0.500 0.134 3.339 3.331 3.326
effect mask 0.366 0.744 2.998 2.991 2.933
effect hand washing 0.897 0.232 3.016 3.003 3.013
country management 0.375 0.143 1.788 1.775 1.765
community management 0.544 0.013 1.912 1.885 1.880
community action importance 0.710 0.751 3.370 3.369 3.367
community action norms 0.503 0.695 2.711 2.704 2.679
distancing importance 0.882 0.841 3.150 3.148 3.149
norms dist 0.523 0.917 49.914 49.721 49.237
norms masks 0.693 0.447 73.143 72.896 71.308
norms vaccine 0.521 0.829 62.837 62.512 60.816
risk community 0.813 0.331 2.547 2.545 2.515
risk infection 0.460 0.771 2.218 2.208 2.179
control infection 0.242 0.498 1.880 1.872 1.849
infection severity 0.323 0.554 1.255 1.258 1.264
employed 2020 0.707 0.152 0.731 0.722 0.733
Pre-treatment covariate means for all respondents who were treated, completed the entire survey,
and received a full survey completion weight along with the p-value for the test of the null that the
means between treatment groups are equal. For each covariate, only responses where the covariate
is not missing and occurs before both treatment and control are included. To account for changes
to the sampling frequencies, these p-values are from the coefficient on the treatment behavior terms
in a regression of the covariate on treatment behavior, period, and centered interactions between
treatment behavior and period. This is a weighted regression using full completion survey weights.














The results presented in the main text and elaborated on in sections S5, S6, and S6.1 each use
a similar pre-registered methodology that we briefly describe here. For the results in sections
S5 and S6, we estimate the following linear regression for each behavior k










ik + εik (S3)
where Yik is the outcome for individual i and behavior k ∈ K = {vaccine, distancing, masks},
Djik is an indicator if individual i received treatment j ∈ J = {Broad, Narrow} for behavior
k, and Xi is a vector of centered covariatesS50 ,S51 . In the figures and tables, we report the
δjk’s and suppress coefficients on covariates and interactions. All statistical inference uses
heteroskedasticity-consistent Huber–White “sandwich” estimates of the variance–covariance
matrix.
In section S6.1, we estimate a similar regression. As our analysis of heterogeneity focuses















 + εik (S4)
S4.1. Mixed-effects model. In the main text and Figure 3c, we report results from a linear
mixed-effects model with coefficients that vary by country. This model is also described in
our preregistered analysis plan. Note that the coefficients for the overall (across-country)
treatments effects in this model differ slightly from the estimates from the model; that is, the
“Average” points in Figure 3b and 3c do not match exactly. As noted in our analysis plan,
“sandwich” standard errors are not readily available here, so reported 95% confidence intervals
are obtained by estimating the standard errors via a bootstrap.
S5. Effects on beliefs about descriptive norms
Figure S8 present evidence that the treatments do update beliefs about the descriptive norms
of survey respondents. The figures plot coefficients on treatment from a regression of survey
norms on treatment status, including centered covariates and interactions as described in the
pre-analysis plan. In this analysis, treated respondents are those who receive the treatment
before the question eliciting beliefs about norms. This will not agree, in general, with the
treatment status for the main analysis given the randomized question order in the survey. The
covariates included in this analysis are pre-treatment and outcome relative to this treatment














Figure S8a compares treatment and control respondents and figure S8b conditions on treated
individuals and then uses individuals who received an information treatment for a different
behavior as control. The coefficients plotted in figure S8b are smaller than in figure S8a, which
indicates that normative information on other behaviors may induce an update in beliefs on
the focal behavior.
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(b) Treatment vs. Other Behavior Treatment
Fig. S8. Effects on beliefs about descriptive norms
(1) (2) (3) (4) (5) (6)
Broad Treatment 1.250∗∗∗ 0.778 2.719∗∗∗ 2.357∗∗∗ 3.777∗∗∗ 3.685∗∗∗
(0.223) (0.479) (0.198) (0.217) (0.464) (0.168)
Narrow Treatment 0.682∗∗∗ -0.167 0.838∗∗∗ 1.801∗∗∗ 2.955∗∗∗ 1.788∗∗∗
(0.217) (0.477) (0.198) (0.209) (0.463) (0.169)
Control: Other Treatment X X X
Behavior masks dist vaccine masks dist vaccine
Number Controls 149458 34002 91217 229715 52724 225615
Number Treated 75125 17354 130389 75125 17354 130389
Observations 224,583 51,356 221,606 304,840 70,078 356,004
R2 0.170 0.145 0.206 0.182 0.157 0.210
Adjusted R2 0.170 0.143 0.206 0.182 0.156 0.210
Residual Std. Error 25.040 27.046 24.162 25.445 27.085 24.566
F Statistic 130.581∗∗∗ 46.184∗∗∗ 191.547∗∗∗ 201.909∗∗∗ 64.198∗∗∗ 329.570∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table S6. Effects on beliefs about descriptive norms, for primary and alternative definitions of the
control group
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(b) Treatment vs. Other Behavior Treatment
Fig. S9. Treatment effects with primary and alternative definition of the control group
S6. Effects on intentions
Figure S9 displays regression coefficients for the primary analysis, where the intention to
partake in the outcome behavior is regressed on treatment, centered covariates, and their
interactions. As discussed in the pre-analysis plan, we use both the randomized timing of
information treatments and the randomized focal behavior of the intervention. Figure S9a uses
respondents who receive the information after the outcome is measured as the control group
and Figure S9b uses individuals who receive the information treatment for a different behavior
as the control group. The results are largely consistent and suggest that the information
treatment significantly increases reported vaccine acceptance, while effects for distancing and
masks are smaller and not statistically distinguishable from zero.
Table S8 presents results from the same analysis after transforming the outcome variable
into binary indicators. This allows us to understand across which thresholds the treatment
has induced people to cross. The coefficients indicate that the treatment is inducing people to
report they will at least probably take the vaccine and definitely take the vaccine. Similar
regressions restricted to those who report they don’t know if they will take the vaccine at
baseline are presented in Table S9. Among this group, there is a larger effect and it is
concentrated in moving people to say they will “probably” take the vaccine.
S6.1. Heterogeneous treatment effects.Figure S10 plots regression coefficients for estimates
of heterogeneous treatment effects in equation 4 across different dimensions. We see the positive
effects of our treatment concentrated in those with lower baseline beliefs about norms (Figure
S10a) and in those who are unsure if they will accept a vaccine (Figure S10b). Estimates are
also reported in Tables S11 and S12.











(1) (2) (3) (4) (5) (6)
Broad Treatment 0.002 0.001 0.027∗∗∗ 0.011∗ 0.004 0.039∗∗∗
(0.006) (0.014) (0.007) (0.006) (0.014) (0.006)
Narrow Treatment 0.011∗∗ -0.021 0.021∗∗∗ 0.021∗∗∗ -0.017 0.033∗∗∗
(0.006) (0.014) (0.006) (0.005) (0.014) (0.006)
Control: Other Treatment X X X
Behavior masks dist vaccine masks dist vaccine
Number Controls 159962 42237 98940 242238 64323 233076
Number Treated 80847 21296 132517 80847 21296 132517
Observations 240,809 63,533 231,457 323,085 85,619 365,593
R2 0.248 0.234 0.618 0.251 0.244 0.610
Adjusted R2 0.248 0.233 0.617 0.251 0.243 0.610
Residual Std. Error 0.692 0.855 0.805 0.699 0.856 0.812
F Statistic 143.880∗∗∗ 84.485∗∗∗ 989.712∗∗∗ 204.798∗∗∗ 113.443∗∗∗ 1513.455∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Table S7. Treatment effects with primary and alternative definition of the control group
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(a) Baseline Belief Partition
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> No, definitely not > Probably not > Unsure > Probably
Intercept 0.916∗∗∗ 0.846∗∗∗ 0.673∗∗∗ 0.487∗∗∗
(0.001) (0.001) (0.001) (0.001)
Narrow Treatment 0.000 0.005∗∗∗ 0.011∗∗∗ 0.017∗∗∗
(0.002) (0.002) (0.002) (0.002)
Broad Treatment 0.000 0.005∗∗∗ 0.016∗∗∗ 0.019∗∗∗
(0.002) (0.002) (0.002) (0.002)
Observations 365,593 365,593 365,593 365,593
R2 0.296 0.493 0.560 0.459
Adjusted R2 0.296 0.493 0.560 0.459
Residual Std. Error 0.232 0.257 0.310 0.368
F Statistic 152.334∗∗∗ 577.685∗∗∗ 1647.634∗∗∗ 1508.106∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Estimates of equation 3 with binary outcomes. The outcome variable for each column is an indicator
equal to one if the respondent reported a value higher than the column name. For example, in
the column “> Probably not” the outcome Yi equals one if the respondent answered “Unsure”,
“Probably”, or “Yes, definitely”.
Table S8. Distributional treatment effects
> No, definitely not > Probably not > Unsure > Probably
Intercept 0.968∗∗∗ 0.900∗∗∗ 0.295∗∗∗ 0.046∗∗∗
(0.001) (0.002) (0.003) (0.002)
Narrow Treatment 0.003 0.005 0.025∗∗∗ 0.018∗∗∗
(0.003) (0.004) (0.007) (0.004)
Broad Treatment 0.001 0.006 0.049∗∗∗ 0.015∗∗∗
(0.003) (0.004) (0.007) (0.004)
Observations 69,497 69,497 69,497 69,497
R2 0.111 0.079 0.091 0.063
Adjusted R2 0.109 0.077 0.089 0.061
Residual Std. Error 0.167 0.290 0.448 0.218
F Statistic 6.337∗∗∗ 8.683∗∗∗ 24.288∗∗∗ 8.521∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Estimates of equation 3 with binary outcomes on sample of respondents who say they don’t know if
they will take a vaccine at baseline. The outcome variable for each column is an indicator equal to
one if the respondent reported a value higher than the column name. For example, in the column
“> Probably not” the outcome Yi equals one if the respondent answered “Unsure”, “Probably”, or
“Yes, definitely”.
Table S9. Distributional treatment effects for “Don’t know” respondents












> No, definitely not > Probably not > Unsure > Probably
Intercept 0.876∗∗∗ 0.772∗∗∗ 0.549∗∗∗ 0.358∗∗∗
(0.002) (0.003) (0.003) (0.003)
Narrow Treatment 0.001 0.012∗∗ 0.019∗∗∗ 0.017∗∗∗
(0.005) (0.005) (0.006) (0.007)
Broad Treatment -0.001 0.005 0.019∗∗∗ 0.020∗∗∗
(0.005) (0.005) (0.006) (0.006)
Observations 48,699 48,699 48,699 48,699
R2 0.357 0.534 0.580 0.472
Adjusted R2 0.355 0.532 0.578 0.471
Residual Std. Error 0.266 0.287 0.324 0.352
F Statistic 43.277∗∗∗ 176.441∗∗∗ 374.368∗∗∗ 175.635∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Estimates of equation 3 with binary outcomes on sample of respondents who have a baseline beliefs
about how many people in their community will take a vaccine under the narrow treatment number.
The outcome variable for each column is an indicator equal to one if the respondent reported a
value higher than the column name. For example, in the column “> Probably not” the outcome Yi
equals one if the respondent answered “Unsure”, “Probably”, or “Yes, definitely”.
Table S10. Distributional treatment effects for “Under” respondents
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Heterogeneous treatment effects based on baseline beliefs about how many people in their
community will accept a vaccine. We remove subjects who respond they believe 0, 50, or
100 percent of people in their community will accept a vaccine to mitigate measurement
error due to a bias towards round numbers.
Fig. S11. Mitigating Round Number Bias: Baseline Belief Partition













Average Above Between Under
Broad Treatment 0.039∗∗∗ 0.023 0.041∗∗∗ 0.043∗∗∗
(0.006) (0.017) (0.015) (0.016)
Narrow Treatment 0.033∗∗∗ 0.026 0.037∗∗ 0.049∗∗∗
(0.006) (0.017) (0.015) (0.015)
Observations 365,593 30,731 34,008 48,699
R2 0.610 0.394 0.625 0.649
Adjusted R2 0.610 0.391 0.623 0.648
Residual Std. Error 0.812 0.799 0.692 0.826
F Statistic 1513.455∗∗∗ 43.505∗∗∗ 166.301∗∗∗ 329.346∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
The joint test that the broad and narrow coefficients are equal across groups has a p-value of 0.807,
and the two-sided test that the broad (narrow) treatment effects in the Under and Above groups
are equal has a p-value of 0.38 (0.31).
Table S11. Heterogeneous Treatment Effects: Baseline Beliefs
Average No Don’t Know Yes
Broad Treatment 0.039∗∗∗ 0.041∗∗ 0.071∗∗∗ 0.029∗∗∗
(0.006) (0.018) (0.011) (0.006)
Narrow Treatment 0.033∗∗∗ 0.017 0.052∗∗∗ 0.027∗∗∗
(0.006) (0.017) (0.011) (0.006)
Observations 365,593 53,119 69,497 239,822
R2 0.610 0.211 0.114 0.119
Adjusted R2 0.610 0.209 0.112 0.118
Residual Std. Error 0.812 0.994 0.743 0.725
F Statistic 1513.455∗∗∗ 50.166∗∗∗ 19.873∗∗∗ 43.186∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
The joint test that the broad and narrow coefficients are equal across groups has a p-value of 0.012,
and the two-sided test that the broad (narrow) treatment effects in the Yes and Don’t know groups
are equal has a p-value of <0.01 (0.05). The two sided test that the broad (narrow) treatment
effects in the Don’t know and No groups are equal has a p-value of 0.15 (0.08).
Table S12. Heterogeneous Treatment Effects: Baseline Vaccine Acceptance





























Fig. S12. Correlation of Baseline Vaccine Acceptance and Outcome (Detailed) Vaccine Acceptance
Heatmap showing relationship between baseline vaccine acceptance question (x-axis) and the
outcome vaccine acceptance question (y-axis) for the control users. Each cell shows the probability
of an outcome response conditional on the baseline response and each column sums to one.
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(a) Full Sample: High Treatment
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(b) Full Sample: Low Treatment
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(c) Baseline Vaccine Unsure: High Treatment
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(d) Baseline Vaccine Unsure: Low Treatment
Fig. S13. Treatment effect by treatment number
The coefficients reported in these figures are from a regression of vaccine acceptance measured
on a five point scale on indicators of the treatment number the individual was shown (if treated)
grouped into bins of width 10 percentage points. We also include covariates and their interactions
with treatment as in the main analysis. Figures S13a and S13b report the coefficients from the
regression on the full sample of individuals of separate regressions for the high and low treatments.
Figures S13c and S13d report the coefficients from the same regression on the subset of individuals
who reported "Don’t know" to the baseline vaccine acceptance question.













S6.2. Robustness checks.One concern with survey experiments such as ours is the results
could reflect researcher demand effects, where subjects respond how they think the researchers
would want them to respond. While we cannot rule this out completely, we do not believe
this is driving our results cf.S52 ,S53 . We may be less worried about researcher demand effects
in this survey as it has a more general advertised purpose and it covers several topics, so
normative information is not particularly prominent (Figure S4). Furthermore, unlike other
sampling frames with many sophisticated study participants (e.g., Amazon Mechanical Turk),
respondents are recruited from a broader population (Facebook users). In addition, we observe
null results for observable behaviors such as distancing and mask wearing, which we would
expect to suffer from the same researcher demand effects as vaccine acceptance. We also
compare the outcome of subjects who receive the vaccine norm treatment to those receiving
the treatment providing information about masks and distancing and find the treatment
effect persists. Moreover, we may expect researcher demand effects to be smaller when the
information treatment and the outcome are not immediately adjacent. In all cases, for the
vaccine acceptance outcome, there is always at least one intervening screen of questions
(the future mask-wearing and distancing intentions questions). Furthermore, they are often
separated by more than this. We consider a subset of respondents where the treatment and
the outcome are separated by at least one “block” of questions between them. Results of this
analysis are presented in Figure S14 and Table S13. The treatment effect estimates on this
smaller sample are less precise, but both positive. For vaccines, the treatment effects muted
somewhat as the p-values that the treatment effect is equal across this smaller sample and the
broader sample are 0.02 and 0.03 for the broad and narrow treatments, respectively. Moreover,
Table S14 shows even with the larger gap between treatment and outcome the information
is still moving a relatively large share of people who are unsure or more negative to at least
probably accepting the vaccine.
Figure S15 plots the distribution of the number of screens between treated and control. In
Figure S15a, we plot the distribution for the entire sample and in Figure S15b we plot the
distribution for the subset of those with at least one block between treatment and control.
For this group there are at least three pages between the treatment and outcome
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(a) Treatment vs. Control
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(b) Treatment vs. Other Behavior Treatment
Fig. S14. Robustness to Researcher Demand Effects
(1) (2) (3) (4) (5) (6)
Broad Treatment -0.001 0.025 0.022∗∗∗ 0.010 0.016 0.030∗∗∗
(0.008) (0.018) (0.008) (0.008) (0.017) (0.007)
Narrow Treatment 0.006 0.005 0.017∗∗ 0.017∗∗ -0.004 0.024∗∗∗
(0.007) (0.018) (0.008) (0.007) (0.017) (0.007)
Control: Other Treatment X X X
Behavior masks dist vaccine masks dist vaccine
Number Controls 105973 27441 65464 160843 41734 154676
Number Treated 53773 13784 88139 53773 13784 88139
Observations 159,746 41,225 153,603 214,616 55,518 242,815
R2 0.222 0.209 0.616 0.226 0.218 0.605
Adjusted R2 0.221 0.207 0.615 0.226 0.216 0.605
Residual Std. Error 0.707 0.865 0.811 0.715 0.870 0.819
F Statistic 89.371∗∗∗ 47.748∗∗∗ 652.743∗∗∗ 123.872∗∗∗ 60.798∗∗∗ 980.206∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Estimates of equation 3 on the restricted sample when outcome and treatment are separated by at
least one additional block of questions.
Table S13. Robustness to Greater Separation of Treatment and Outcome












> No, definitely not > Probably not > Unsure > Probably
Intercept 0.916∗∗∗ 0.846∗∗∗ 0.672∗∗∗ 0.486∗∗∗
(0.001) (0.001) (0.001) (0.002)
Narrow Treatment -0.000 0.002 0.007∗∗ 0.015∗∗∗
(0.002) (0.002) (0.003) (0.003)
Broad Treatment -0.000 0.002 0.013∗∗∗ 0.015∗∗∗
(0.002) (0.002) (0.003) (0.003)
Observations 242,815 242,815 242,815 242,815
R2 0.291 0.490 0.559 0.457
Adjusted R2 0.291 0.490 0.559 0.457
Residual Std. Error 0.234 0.258 0.312 0.369
F Statistic 100.054∗∗∗ 368.874∗∗∗ 1071.256∗∗∗ 998.540∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Estimates of equation 3 on the restricted sample when outcome and treatment are separated by at
least one additional block of questions. The outcome variable in this analysis are binary indicators
if the outcome was at least a certain response as in table S8.
Table S14. Robustness to Greater Separation of Treatment and Outcome: Distributional Treatment
Effects
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(b) Number of Screens Between Treatment and Out-
come in Robustness Check Sample
Fig. S15. Separation of Treatment and Outcome
(a) Histogram of the number of screens between treatment and outcome. Negative numbers
represent treated respondents and positive numbers are control respondents. The distribution is not
smooth as the randomized order is at the block level, and blocks have varying number of screens
(pages) within them. (b) The same histogram, but for the set of respondents with at least one
block between treatment and outcome.














In the main text, Figure 1 (inset) shows the association between beliefs about descriptive
norms and intentions to accept a COVID-19 vaccine. Figure S16 disaggregates this information
by country. As in the main text, this is a purely observational association but is computed on
the main experimental sample (i.e., starting in late October).
United Kingdom United States Vietnam
Philippines Poland Romania Thailand Turkey
Japan Malaysia Mexico Nigeria Pakistan
France Germany India Indonesia Italy
Argentina Bangladesh Brazil Colombia Egypt
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Beliefs about descrptive norms
Fig. S16. People who believe a larger fraction of their community will accept a vaccine are on average
more likely to say they will accept a vaccine and this is true within the 23 included countries. The vertical
axis shows the percentage of respondents who replied Yes (green), Don’t know (gray) and No (brown) to
whether they will accept a COVID-19 vaccine.













S8. Validating survey data
At the time of this writing, vaccinations are not available to the vast majority of people in the
sample and it is difficult to compare intentions with actual take-up due to supply constraints.
In an attempt to quantity the link between survey responses and behavior, we run an auxiliary
analysis comparing self-reported COVID-19 from the survey with country level uptake.††
The estimated vaccinated share of adults from the survey measure is highly predictive of the









Residual Std. Error 4.488
F Statistic 25.183∗∗∗
∗p<0.1; ∗∗p<0.05; ∗∗∗p<0.01
Regression of true vaccination share on estimated share vaccinated based on the survey measure.
There are only 22 observations rather than 23 because data on the true share vaccinated are
unavailable in Egypt. Adjustment for attenuation bias due to measurement error in the survey
results in nearly identical results.
Table S15. Survey Data Predictive of Cross-Sectional Vaccine Take-up
††COVID-19 vaccine data retrieved from https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations.
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3782082
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